The independent impact of newborn hepatitis B vaccination on reducing HBV prevalence in China, 1992-2006: A mathematical model analysis

Journal of Theoretical Biology

Volumn 386, Issue , 2015, Pages 115-121

  Liang, Peifeng ^a   Zu, Jian ^a   Yin, Juan ^a   Li, Hao ^a   Gao, Longfei ^a   Cui, Fuqiang ^b   Wang, Fuzhen ^b   Liang, Xiaofeng ^b   Zhuang, Guihua ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Age structure; Contribution rate; Discrete dynamic model; HBV transmission

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B VACCINE;

AGE STRUCTURE; DISEASE PREVALENCE; DISEASE TRANSMISSION; HEPATITIS; HUMAN IMMUNODEFICIENCY VIRUS; NEONATE; NUMERICAL MODEL; VACCINATION;

ARTICLE; CHINA; DRUG DOSE REGIMEN; FATALITY; HEPATITIS B; HUMAN; INFECTION CONTROL; MATHEMATICAL MODEL; NEWBORN; PREVALENCE; PRIORITY JOURNAL; PROGRAM IMPACT; TIME SERIES ANALYSIS; VACCINATION; VIRUS TRANSMISSION; BIOLOGICAL MODEL; HEPATITIS B, CHRONIC; PREVENTIVE HEALTH SERVICE; TRANSMISSION;

CHINA;

HEPATITIS B VIRUS;

CHINA; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION PROGRAMS; INFANT, NEWBORN; MODELS, BIOLOGICAL; PREVALENCE; VACCINATION;

EID: 84943265064     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2015.08.030     Document Type: Article

References (42)

1. Anderson R.M., May R.M. Vaccination and herdimmunity to infection diseases. Nature 1985, 318:323-329.
2. Anderson R.M., May R.M. Immunisation and herd immunity. Lancet 1990, 335:641-645.
3. Bortolotti F., Guido M., Bartolacci S., Cadrobbi P., Crivellaro C., Noventa F., Morsica G., Moriondo M., Gatta A. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006, 43:556-562.
4. Chan C.Y., Lee S.D., Lo K.J. Legend of hepatitis B vaccination: the Taiwan experience. J. Gastroenterol. Hepatol. 2004, 19:121-126.
5. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., Shau W.Y., Chen D.S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 1997, 336:1855-1859.
6. Chu C.M., Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007, 45:1187-1192.
7. Dai Z.C., Qi G.M. Viral Hepatitis in China: Seroepidemiological Survey in Chinese Population, 1992-1995 (Part one) 1999, Scientific and Technical Documents Publishing House, Beijing.
8. de Franchis R., Hadengue A., Lau G., Lavanchy D., Lok A., McIntyre N., Mele A., Paumgartner G., Pietrangelo A., Rodés J., Rosenberg W., Valla D. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus Statement (long version). J. Hepatol. 2003, 39(Suppl. 1):S3-S25.
9. Edmunds W.J., Medley G.F., Nokes D.J., O'Callaghan C.J., Whittle H.C., Hall A.J. Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol. Infect. 1996, 117:313-325.
10. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol. 2005, 34:1329-1339.
11. Hsu H.Y., Chang M.H., Hsieh K.H., Lee C.Y., Lin H.H., Hwang L.H., Chen P.J., Chen D.S. Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology 1992, 15:770-776.
12. Kretzschmar M., de Wit G.A., Smits L.J., van de Laar M.J. Vaccination against hepatitis B in low endemic countries. Epidemiol. Infect. 2002, 128:229-244.
13. Kretzschmar M., Mangen M.J., van de Laar M., de Wit A. Model based analysis of hepatitis B vaccination strategies in the Netherlands. Vaccine 2009, 27:1254-1260.
14. Lee C., Gong Y., Brok J., Boxall E.H., Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. Br. Med. J. 2006, 332:328-336.
15. Liang X.F., Bi S.L., Yang W.Z., Wang L.D., Cui G., Cui F.Q., Zhang Y., Liu J., Gong X., Chen Y., Wang F., Zheng H., Wang F., Guo J., Jia Z., Ma J., Wang H., Luo H., Li L., Jin S., Hadler S.C., Wang Y. Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009, 27:6550-6557.
16. Liang X.F., Bi S.L., Yang W.Z., Wang L.D., Cui G., Cui F.Q., Zhang Y., Liu J., Gong X., Chen Y., Wang F., Zheng H., Wang F., Guo J., Jia Z., Ma J., Wang H., Luo H., Li L., Jin S., Hadler S.C., Wang Y. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J. Infect. Dis. 2009, 200:39-47.
17. Liang X.F., Chen Y.S., Wang X.J., He X., Chen L.J., Wang J. A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old. Chin. J. Epidemiol. 2005, 26:655-658.
18. Liaw Y.F., Sheen I.S., Chen T.J., Chu C.M., Pao C.C. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991, 13:627-631.
19. Liaw Y.F., Chu C.M. Hepatitis B virus infection. Lancet 2009, 373:582-592.
20. Lin H.H., Wang L.Y., Hu C.T., Huang S.C., Huang L.C., Lin S.S., Chiang Y.M., Liu T.T., Chen C.L. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J. Med. Virol. 2003, 69:471-474.
21. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009, 49(Suppl. 5):S45-S55.
22. Medley G.F., Lindop N.A., Edmunds W.J., Nokes D.J. Hepatitis-B virus endemicity: heterogeneity, catastrophic dynamics and control. Nat. Med. 2001, 7:619-624.
23. Muench H. Catalytic Models in Epidemiology 1959, Harvard University Press, Cambridge, Massachusetts.
24. Pang J., Cui J.A., Zhou X. Dynamical behavior of a hepatitis B virus transmission model with vaccination. J. Theor. Biol. 2010, 265:572-578.
25. Perz J.F., Elm J.L., Fiore A.E., Huggler J.I., Kuhnert W.L., Effler P.V. Near elimination of hepatitis B virus infections among Hawaii elementary school children after universal infant hepatitis B vaccination. Pediatrics 2006, 118:1403-1408.
26. Qi X.Q., Wang Y. Seroepidemiological Survey of Hepatitis B in Chinese Population 2011, People's Medical Publishing House, Beijing.
27. Romano L., Paladini S., Van Damme P., Zanetti A.R. The worldwide impact of vaccination on the control and protection of viral hepatitis B. Dig. Liver Dis. 2011, 43(Suppl. 1):S2-S7.
28. Shouval D. Hepatitis B vaccines. J. Hepatol. 2003, 39:70-76.
29. Tang J.R., Hsu H.Y., Lin H.H., Ni Y.H., Chang M.H. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J. Pediatr. 1998, 133:374-377.
30. Viviani S., Jack A., Hall A.J., Maine N., Mendy M., Montesano R., Whittle H.C. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 1999, 17:2946-2950.
31. Whittle H.C., Maine N., Pilkington J., Mendy M., Fortuin M., Bunn J., Allison L., Howard C., Hall A. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995, 345:1089-1092.
32. Williams I.T., Goldstein S.T., Tufa J., Tauillii S., Margolis H.S., Mahoney F.J. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr. Infect. Dis. J. 2003, 22:157-163.
33. Williams J.R., Nokes D.J., Medley G.F., Anderson R.M. The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol. Infect. 1996, 116:71-89.
34. World Health Organization WHO Guide for Standardization of Economic Evaluations of Immunization Programmes 2008, WHO Press, Geneva.
35. World Health Organization Hepatitis B vaccines: WHO position paper. Wkly. Epidemiol. Rec. 2009, 84:405-419.
36. Xia G.L., Liu C.B., Cao H.L., Bi S.L., Zhan M.Y., Su C.A., Nan J.H., Qi X.Q. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int. Hepatol. Commun. 1996, 5:62-73.
37. Yukich J., Briët O., Bretscher M.T., Bennett A., Lemma S., Berhane Y., Eisele T.P., Keating J., Smith T. Estimating Plasmodium falciparum transmission rates in low-endemic settings using a combination of community prevalence and health facility data. PLoS One 2012, 7:e42861.
38. Zanetti A.R., Van Damme P., Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008, 26:6266-6273.
39. Zhang S.X., Zhou Y.C. The analysis and application of an HBV model. Appl. Math. Model. 2012, 36:1302-1312.
40. Zhao S.J., Xu Z.Y., Lu Y. A mathematical model of hepatitis B virus transmission and its application for vaccination strategy in china. Int. J. Epidemiol. 2000, 29:744-752.
41. Zhuang G.H., Pan X.J., Wang X.L. A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China. Vaccine 2008, 26:4608-4616.
42. Zou L., Zhang W., Ruan S. Modeling the transmission dynamics and control of hepatitis B virus in China. J. Theor. Biol. 2010, 262:330-338.